奥沙利铂联合卡培他滨同步放化疗治疗中晚期贲门癌临床观察

目的:观察奥沙利铂联合卡培他滨同步放化疗治疗晚期贲门癌的疗效。方法:将67例中晚期贲门癌患者随机分为两组,放化疗同步组29例采用2Gy/次,共60Gy/6周,同时以奥沙利铂100mg第1、8天加卡培他滨1000mg口服,2次/d,第1～15天,方案,每3周1周期,共2周期;单纯放疗组38例采用2Gy/次,共60Gy/6周。结果:同步放化疗组和单纯放疗组CR分别为3.4%、0%(P>0.05),两组PR分别为79.3%、31.6%(P<0.01),同步放化疗副反应发生率高于单纯放疗组,其中主要为度白细胞计数降低发生率分别为44.8%、0%(P<0.05),～度周围神经炎反生率分别为13.8%、0%(P<0.05),经对症处理后患者均耐受良好。结论:奥沙利铂联合卡培他滨同步放化疗治疗中晚期贲门癌是较单纯放疗疗效好、副作用较轻的治疗方法,值得进一步研究。

Clinical observation of radiotherapy combined with synchronous chemotherapy with oxaliplatin and capecitabine for advanced cardia cancer

Objective：To observe the efficacy and adverse effects of radiotherapy combined with synchronous chemotherapy using oxaliplatin and capecitabine for advanced cardia cancer. Methods ：The patients with advanced cardia cancer were divided into two groups,the patients in the treatment group 29 cases were received the treatment of 6000cGy radiotherapy for 6 weeks and 2 cycles of synchronous chemotherapy with Oxaliplatin 100mg （in the first day and eighth day ） and Capecitabine 1000mg （take orally in the day 1 to 15 ） in 21 days, The control group 38 cases were received the treatment of 6000cGy radiotherapy for 6 weeks, The efficacy and adverse effects were analyzed after four weeks of the treatment. Results ： The CR of the two groups were 3. 4% ,0% respectively （χ^2=1. 354,P=0. 245）, but the PR of the group with radiotherapy and synchronous chemotherapy was significantly higher than that in the control group （78.3% VS 31. 2%, χ^2=44. 721, P=0. 000）. The adverse effects of the treatment group were more serious than those in control group, especially, the incidence of grade Ⅱ depress of WBC was 44.8%,0% respectively（P〈0. 05）, moreover, The incidence of the reversible grade Ⅰ - Ⅱ neurosensory toxicity was 13. 8%, 0% respectively （P〈0. 05）. Conclusion：Radiation combined with synchronous chemotherapy with oxaliplatin and capecitabine show good efficacy andtolerable toxicity in treatment of patients with advanced cardia cancer.